• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Rotarix (Rotavirus Vaccine, Live, Oral)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Rotarix (Rotavirus Vaccine, Live, Oral)

  • Profile

Profile

Contact Information

Contact: GlaxoSmithKline
Website: https://gskpro.com/en-us/products/rotarix/

Currently Enrolling Trials

    Show More

    General Information

    Rotarix is a live, attenuated rotavirus vaccine derived from the human 89-12 strain, which belongs to G1P[8] type. Rotarix replicates in the small intestine and induces immunity. The exact immunologic mechanism by which Rotarix protects against rotavirus gastroenteritis is unknown.

    Rotarix is specifically indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4 and G9) when administered as a two-dose series in infants and children.

    Mechanism of Action

    Rotarix is a live, attenuated rotavirus vaccine derived from the human 89-12 strain, which belongs to G1P[8] type. The rotavirus strain is propagated on Vero cells. After reconstitution, the final formulation (1 mL) contains at least 106.0 median Cell Culture Infective Dose (CCID50) of live, attenuated rotavirus. The exact immunologic mechanism by which Rotarix protects against rotavirus gastroenteritis is unknown.

    Side Effects

    Adverse events associated with the use of Rotarix may include, but are not limited to, the following:

    • fussiness/irritability
    • cough/runny nose/fever
    • loss of appetite
    • loss of appetite
    • diarrhea
    • dehydration
    • gastroenteritis

    Dosing/Administration

    Rotarix is supplied as a vial of lyophilized vaccine to be reconstituted with a liquid diluent designed for oral administration. The vaccination series consists of two 1-mL doses administered orally. It is recommended that the first dose be administered to infants beginning at 6 weeks of age. There should be an interval of at least 4 weeks between the first and second dose. The two-dose series should be completed by 24 weeks of age.

    Clinical Trial Results

    FDA Approval was based on the results of four clinical trials.

    Efficacy Evaluation of Rotarix through One Rotavirus Season
    This randomized, double-blind, placebo-controlled study enrolled 3,994 infants in Europe. Vaccine or placebo was given to healthy infants as a two-dose series, with the first dose administered orally from 6 through 14 weeks of age followed by one additional dose administered at least four weeks after the first dose. The two-dose series was completed by 24 weeks of age. The primary efficacy endpoint was prevention of any grade of severity rotavirus gastroenteritis caused by naturally occurring rotavirus from two weeks after the second dose through one rotavirus season. Other efficacy evaluations included prevention of severe rotavirus gastroenteritis, as defined by the Vesikari scale, and reductions in hospitalizations due to rotavirus gastroenteritis and all cause gastroenteritis regardless of presumed etiology. Analyses were also done to evaluate the efficacy of Rotarix against rotavirus gastroenteritis among infants who received at least one vaccination (total vaccinated cohort, TVC). Efficacy of Rotarix against any grade of severity of rotavirus gastroenteritis through one rotavirus season was 87.1 percent (95 percent CI: 79.6, 92.1); TVC efficacy was 87.3 percent (95 percent CI: 80.3, 92.0). Efficacy against severe rotavirus gastroenteritis through one rotavirus season was 95.8 percent (95 percent CI: 89.6, 98.7); TVC efficacy was 96.0 percent (95 percent CI: 90.2, 98.8). The protective effect of Rotarix against any grade of severity of rotavirus gastroenteritis observed immediately following dose 1 administration and prior to dose 2 was 89.8 percent (95 percent CI: 8.9, 99.8). Efficacy of Rotarix in reducing hospitalizations for rotavirus gastroenteritis through one rotavirus season was 100 percent (95 percent CI: 81.8, 100); TVC efficacy was 100 percent (95 percent CI: 81.7, 100). Rotarix reduced hospitalizations for all cause gastroenteritis regardless of presumed etiology by 74.7 percent (95 percent CI: 45.5, 88.9).

    Efficacy Evaluation of Rotarix through One Year
    This randomized, double-blind, placebo-controlled study enrolled 63,225 infants in Latin America and Finland. Vaccine or placebo was given to healthy infants as a two-dose series with the first dose administered orally from 6 through 13 weeks of age followed by one additional dose administered at least four weeks after the first dose. The two-dose series was completed by 24 weeks of age. The primary efficacy endpoint was prevention of severe rotavirus gastroenteritis caused by naturally occurring rotavirus from two weeks after the second dose through one year (ATP). Analyses were done to evaluate the efficacy of Rotarix against severe rotavirus gastroenteritis among infants who received at least one vaccination (TVC). Reduction in hospitalizations due to rotavirus gastroenteritis was also evaluated (ATP). Efficacy of Rotarix against severe rotavirus gastroenteritis through one year was 84.7 percent (95 percent CI: 71.7, 92.4); TVC efficacy was 81.1 percent (95 percent CI: 68.5, 89.3). Efficacy of Rotarix in reducing hospitalizations for rotavirus gastroenteritis through one year was 85.0 percent (95 percent CI: 69.6, 93.5); TVC efficacy was 80.8 percent (95 percent CI: 65.7, 90.0).

    Efficacy through Two Rotavirus Seasons
    The efficacy of Rotarix persisting through two rotavirus seasons was evaluated in two studies.
    European Study
    The efficacy of Rotarix against any grade of severity of rotavirus gastroenteritis through two rotavirus seasons was 78.9 percent (95 percent CI: 72.7, 83.8). Efficacy in preventing any grade of severity of rotavirus gastroenteritis cases occurring only during the second season post-vaccination was 71.9 percent (95 percent CI: 61.2, 79.8). The efficacy of Rotarix against severe rotavirus gastroenteritis through two rotavirus seasons was 90.4 percent (95 percent CI: 85.1, 94.1). Efficacy in preventing severe rotavirus gastroenteritis cases occurring only during the second season post-vaccination was 85.6 percent (95 percent CI: 75.8, 91.9). The efficacy of Rotarix in reducing hospitalizations for rotavirus gastroenteritis through two rotavirus seasons was 96.0 percent (95 percent CI: 83.8, 99.5).
    Latin American Study
    The efficacy of Rotarix against severe rotavirus gastroenteritis through two years was 80.5 percent (95 percent CI: 71.3, 87.1). Efficacy in preventing severe rotavirus gastroenteritis cases occurring only during the second-year, post-vaccination was 79.0 percent (95 percent CI: 66.4, 87.4). The efficacy of Rotarix in reducing hospitalizations for rotavirus gastroenteritis through two years was 83.0 percent (95 percent CI: 73.1, 89.7).

    Efficacy Against Specific Rotavirus Types
    The type-specific efficacy against any grade of severity and severe rotavirus gastroenteritis caused by G1P[8], G3P[8], G4P[8], G9P[8], and combined non-G1 (G2, G3, G4, G9) types was statistically significant through one year. Additionally, type-specific efficacy against any grade of severity and severe rotavirus gastroenteritis caused by G1P[8], G2P[4], G3P[8], G4P[8], G9P[8], and combined non-G1 (G2, G3, G4, G9) types was statistically significant through two years.

    Ongoing Study Commitments

    • GlaxoSmithKline has agreed to a large-scale observational post-licensure safety study in the U.S to assess the potential serious risk of intussusception and other serious adverse effects (specifically Kawasaki disease, hospitalizations due to acute lower respiratory tract infections, and convulsions) in recipients of ROTARIX. The study will include approximately 44,000 vaccinated subjects (adjustments to the sample size will be made based on the background rate of intussusception). The study will be designed to detect an increased relative risk of intussusception due to vaccine with a relative risk of 2.5 or greater and with 80 percent power.
      Protocol Submission: November 2008
      Study Start: June 2009
      Final Report Submission: March 2012

     

    Approval Date: 2008-04-01
    Company Name: GlaxoSmithKline
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing